Comparative Pharmacology
Head-to-head clinical analysis: HALOTEX versus KETOZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOTEX versus KETOZOLE.
HALOTEX vs KETOZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Halotex (haloprogin) is a topical antifungal agent that disrupts fungal cell membrane permeability and inhibits ergosterol synthesis, leading to cell death.
Ketoconazole is an imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This leads to increased membrane permeability and cell death.
Apply topically twice daily for 2-4 weeks; tinea pedis may require up to 6 weeks.
200 mg orally once daily with food.
None Documented
None Documented
Not well characterized; estimated terminal half-life approximately 24-48 hours based on limited data.
Terminal elimination half-life is approximately 2 hours (range 1.5–3.5 hours). Clinically, duration of antifungal effect extends beyond plasma half-life due to persistent tissue levels.
Primarily fecal (biliary) as unchanged drug and metabolites; negligible renal excretion (<1%).
Primarily hepatic metabolism; renal excretion of unchanged drug <1%. Biliary/fecal excretion accounts for ~20-35% of metabolites.
Category C
Category C
Antifungal
Antifungal